Navigation Links
Atherotech Receives Patent for ApoB Measurement
Date:5/19/2009

Patent recognizes accurate method in the VAP(R) Cholesterol Test for determining heart disease risk

BIRMINGHAM, Ala., May 19 /PRNewswire/ -- Atherotech, Inc., developer of the VAP Cholesterol Test, has announced it has received a patent on its method to derive and report apolipoprotein B100 (apoB) using the Vertical Auto Profile (VAP) technology. The patent recognizes the unique ability of the VAP Cholesterol Test to accurately report apoB, the next milestone in heart disease risk assessment.

The patent, issued April 21, 2009, states that Atherotech provides a "system and method that measures the concentration of apoB without requiring a separate apoB specific test." Atherotech added apoB measurement to its VAP Test in 2007 and has since reported more than 1 million apoB results. The VAP Test is the only single cholesterol test that routinely reports apoB.

ApoB is a protein found on all atherogenic (bad) lipoproteins present in blood circulation, and elevated apoB values represent increased risk for heart disease. In numerous well-designed prospective studies, apoB has been shown to be superior to LDL cholesterol in predicting cardiovascular events and in following the progression of heart disease. ApoB is particularly valuable in hypertriglyceridemic and insulin-resistant states where LDL levels would be falsely reassuring and not representative of true atherosclerotic particle burden.

"ApoB is much more predictive of risk than LDL," noted Michael Cobble, M.D., director of Canyons Medical Center in Sandy, Utah. Cobble is a primary care physician, board-certified lipidologist and certified hypertension specialist. "It aligns with non-HDL and VLDL more accurately and is an important treatment target recently confirmed by both the American College of Cardiology and the American Diabetes Association."

People with a family history or an existing condition of diabetes, high blood pressure or heart disease - or who are already taking cholesterol lowering medication - are candidates for the comprehensive VAP Test, according to Atherotech President Mike Mullen.

"The single VAP Test reports over 20 separate values, including apoB, eliminating the need for nine separate tests that would have to be run in a typical laboratory setting," commented Mullen. "The VAP Test is now well positioned to be the market leader in advanced lipid testing. It has the comprehensive lipid reporting that an increasing number of physicians and practices are requesting without the added cost, which fits nicely in our current economic and health care environment."

Mullen said the patent should have a positive impact on his company's business.

"We expect to see an increase in orders for our VAP Test because of its clinically validated ability to accurately report apoB and because it is quickly becoming more of a standard in determining heart disease risk in cholesterol testing."

The VAP Test is available nationwide and covered by most insurance providers, including Medicare and Medicaid. For more information call 877.901.8510 or visit www.thevaptest.com.

About Atherotech, Inc.

Atherotech is a cardio-diagnostic company focusing on cardiometabolic tests, including the company's patented VAP Cholesterol Test, which reports the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for direct LDL measurement, which is accurate with non-fasting samples. It is the only advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the American Diabetes Association and American College of Cardiology expert consensus guidelines. The VAP Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit www.thevaptest.com.


'/>"/>
SOURCE Atherotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Atherotech to Exhibit its VAP(R) Cholesterol Test at Internal Medicine 2009 in Philadelphia
2. Atherotech Unveils New Cardiometabolic Test Panels
3. Atherotech to Exhibit the VAP(R) Cholesterol Test at ACC.09 in Orlando
4. Atherotech Announces Addition of ApoAI Heart Disease, Diabetes Risk Marker to VAP(R) Test
5. Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008
6. VAP(R) Cholesterol Test From Atherotech Covers an Additional 9 Million of Florida Insured
7. Atherotech to Exhibit the VAP Test at Internal Medicine 2008
8. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
9. Atherotech to Exhibit the VAP Test (R) at ACC 2008 Meeting in Chicago
10. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
11. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Recent ... cell type. Many treatments for specific cancers, such as breast, prostate, or lung, ... is androgen deprivation therapy for advanced prostate cancer. , This therapy limits ...
(Date:8/16/2017)... ... August 16, 2017 , ... Today, 3Bar ... has secured $2M in funding from an impressive group of investors, including Rev1 ... Thrive Fund. With this investment, 3Bar is broadening availability of its groundbreaking offering ...
(Date:8/16/2017)... edition of the Inc. 5000 features a now-familiar name: BioPoint ( http://biopointinc.com/ ... list for the third year in a row. Now in its 36th ... a set of quantitative metrics. In addition, BioPoint was also named to ... Bay State . ... ...
(Date:8/15/2017)... , Aug. 15, 2017 After spending the past ... support with crowdsourced data collection, GeneFo now offers this platform to ... aligning and amplifying support, adherence, and data collection vis a vis ... foundations mark the successful launch of this offer. ... GeneFo ...
Breaking Biology Technology:
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
Breaking Biology News(10 mins):